Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoantibodies in systemic sclerosis.

Virginia D Steen1

  • 1Department of Medicine, Georgetown University, Washington, DC 2007, USA. steenv@georgetown.edu

Seminars in Arthritis and Rheumatism
|August 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

The Journal of rheumatology·2025
Same author

'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.

Rheumatology (Oxford, England)·2025
Same author

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.

Annals of the American Thoracic Society·2025
Same journal

Optimizing the use of patient-reported outcome measures in axial spondyloarthritis: a mixed-methods study from the QUESTIONAX Project.

Seminars in arthritis and rheumatism·2026
Same journal

Barriers and enablers to the implementation of osteoarthritis management programmes in primary or community care settings: A systematic review and qualitative framework synthesis.

Seminars in arthritis and rheumatism·2026
Same journal

Predictors of relapse, early escalation and 1-Year use of glucocorticoids in new-onset polymyalgia rheumatica: A prospective cohort study.

Seminars in arthritis and rheumatism·2026
Same journal

Postoperative complications and outcomes after surgical treatment for tophaceous gout: A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2026
Same journal

Effectiveness and safety of primary thromboprophylaxis in antiphospholipid antibody carriers by serological 2023 ACR/EULAR domains.

Seminars in arthritis and rheumatism·2026
See all related articles

Scleroderma autoantibodies are linked to distinct patient demographics, clinical signs, and organ outcomes. Identifying these antibodies aids in predicting prognosis and guiding treatment for scleroderma patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Scleroderma is a complex autoimmune disease characterized by fibrosis and vascular abnormalities.
  • Specific autoantibodies are recognized as biomarkers for different scleroderma subtypes and clinical manifestations.

Purpose of the Study:

  • To elucidate the demographic, clinical, and prognostic characteristics associated with specific scleroderma autoantibodies.
  • To establish correlations between autoantibody profiles and disease phenotypes, organ involvement, and patient survival.

Main Methods:

  • Retrospective analysis of 1980-1995 Pittsburgh Scleroderma Databank cohort.
  • Assay of anticentromere antibodies (ACA), antitopoisomerase (TOPO), anti-U1-RNP (U1-RNP), anti-RNA Polymerase III (Pol 3), anti-U3-RNP (U3-RNP), anti-Th/To (Th/To), and anti-Pm/Scl (Pm/Scl).

Related Experiment Videos

  • Comparison of clinical features, organ outcomes, and survival rates across different autoantibody groups.

    • Main Results:

    • Specific autoantibodies correlated with demographic factors (e.g., ACA in older Caucasian females, U3-RNP/U1-RNP/TOPO in African-Americans).
    • Distinct clinical associations observed: muscle inflammation (U1-RNP, U3-RNP), digital ulcers (ACA, TOPO), pulmonary hypertension (ACA), pulmonary fibrosis (TOPO), and renal crisis (Pol 3).
    • Pol 3 antibodies were associated with rare severe interstitial fibrosis but the best survival in diffuse scleroderma; Th/To antibodies were linked to decreased survival in limited scleroderma.

    Conclusions:

    • Scleroderma autoantibodies exhibit highly specific associations with demographic, clinical, organ system, and survival features.
    • Autoantibody determination is a valuable tool for prognosis assessment, patient monitoring, and therapeutic strategy development in scleroderma.